A phase III, double-blind, randomized, placebo-controlled study to assess the efficacy and safety of selumetinib (AZD624; ARRY-142886) Hyd-Sulfate) in combination with Docetaxel, in patients receiving second line treatment for KRAS Mutation-Positive